0000887359 false 0000887359 2022-02-16 2022-02-16 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

 

 

Date of Report (Date of Earliest Event Reported): February 16, 2022

 

Vericel Corporation

(Exact name of registrant as specified in its charter)

  

Michigan   001-35280   94-3096597

(State or other

jurisdiction of

 

(Commission File

Number)

 

(I.R.S. Employer

Identification No.)

incorporation)        

 

64 Sidney Street  
Cambridge, MA 02139
(Address of principal executive offices) (Zip Code)

 

Registrant’s telephone number, including area code: (617)-588-5555

 

Not Applicable

Former name or former address, if changed since last report

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, no par value   VCEL   NASDAQ

 

Indicate by a check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§240.12b-2 of this chapter). Emerging Growth Company ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

 

 

 

 

 

 

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

On February 16, 2022, Jonathan Siegal, Vericel Corporation’s (the “Company”) Vice President and Corporate Controller was appointed principal accounting officer, effective immediately. Mr. Siegal replaces Joseph Mara who was acting as the Company’s principal accounting officer.

 

Mr. Siegal, age 43, has served as Vice President and Corporate Controller of the Company since September 2021. Prior to joining Vericel, Mr. Siegal was employed by Lantheus Medical Imaging from 2016 until 2021, most recently as Senior Director, Global Controller. He also has additional controllership and accounting experience within the United States across other industries. Mr. Siegal is a C.P.A, and he has a B.A. in Accounting & Economics from Gordon College.

 

There are no arrangements or understandings between Mr. Siegal and any other persons pursuant to which he became the Company’s principal accounting officer. There is no family relationship between Mr. Siegal and any director, executive officer, or person nominated or chosen by the Company to become a director or executive officer at the Company. The Company has not entered into any transactions with Mr. Siegal that would require disclosure pursuant to Item 404(a) of Regulation S-K under the Securities Exchange Act of 1934, as amended. As of the date of this Current Report on Form 8-K, no new compensatory arrangements have been entered into with Mr. Siegal in connection with his appointment as the Company’s principal accounting officer.

 

Following Mr. Siegal’s appointment, Mr. Mara will continue to serve as Chief Financial Officer and as the Company’s principal financial officer.

 

Item 9.01. Financial Statements and Exhibits.

 

Exhibit No.   Description
99.1   Press Release of Vericel Corporation, dated February 24, 2022
104   Cover Page Interactive Data File (embedded within the Inline XBRL)

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  Vericel Corporation
     
Date:  February 24, 2022 By: /s/ Sean C. Flynn
    Name: Sean C. Flynn
    Title: Vice President, General Counsel and Secretary

 

 

 

Exhibit 99.1 

 

Vericel Corporation

64 Sidney Street

Cambridge, MA 02139

T 617 588-5555     F 617 588-5554

www.vcel.com

 

Vericel Announces Appointment of Jonathan Siegal as Principal Accounting Officer

 

CAMBRIDGE, Mass., February 24, 2022 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Board of Directors has appointed Jonathan Siegal as the Company’s Principal Accounting Officer, effective February 16, 2022. Mr. Siegal is currently serving as Vericel’s Vice President and Corporate Controller.

 

Mr. Siegal joined Vericel in September 2021 with over 20 years of accounting and financial leadership experience across a variety of industries in both the public and private sectors. Before joining Vericel, Mr. Siegal most recently served as Global Controller for Lantheus Medical Imaging, where he led the company’s accounting function and served as a leader across the financial organization. Prior to joining Lantheus in 2016, he served in a number of accounting and controllership roles of increasing responsibility across a variety of industries. Mr. Siegal is a C.P.A. and earned a B.A. in Accounting and Economics from Gordon College.

 

As Corporate Controller and principal accounting officer, Mr. Siegal will continue to report to Vericel’s Chief Financial Officer Joe Mara. “We are pleased to announce Jon’s appointment,” said Mr. Mara. “His extensive background and deep accounting and leadership experience has helped strengthen an already talented finance team at Vericel.”

 

About Vericel Corporation

 

Vericel is a leader in advanced therapies for the sports medicine and severe burn care markets. The company markets two cell therapy products in the United States. MACI® (autologous cultured chondrocytes on porcine collagen membrane) is an autologous cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Epicel® (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area. The company also holds an exclusive license for North American rights to NexoBrid®, a registration-stage biological orphan product for debridement of severe thermal burns. For more information, please visit the company’s website at www.vcel.com.

 

Epicel® and MACI® are registered trademarks of Vericel Corporation. NexoBrid® is a registered trademark of MediWound Ltd. and is used under license to Vericel Corporation. © 2022 Vericel Corporation. All rights reserved.

 

Investor Contacts:

Eric Burns

ir@vcel.com

+1 (734) 418-4411